Annette K Larsen

Summary

Country: France

Publications

  1. doi request reprint Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
    Annette K Larsen
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Hopital Saint Antoine, Paris 75012, France
    Pharmacol Ther 131:80-90. 2011
  2. doi request reprint EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    Virginie Poindessous
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    Clin Cancer Res 17:6522-30. 2011
  3. doi request reprint Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Institut National de la Santé et de la Recherche Médicale U938, Paris, France
    Mol Cancer Ther 10:1481-9. 2011
  4. doi request reprint The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
  5. doi request reprint Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem J 437:63-73. 2011
  6. doi request reprint From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
  7. pmc Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
  8. doi request reprint The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators
    Céline J Rocca
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem Pharmacol 80:335-43. 2010
  9. doi request reprint Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions
    Benoist Chibaudel
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 9:269-73. 2010
  10. ncbi request reprint Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models
    Amélie Petitprez
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75012, France
    Curr Pharm Des 19:958-64. 2013

Collaborators

Detail Information

Publications13

  1. doi request reprint Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
    Annette K Larsen
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Hopital Saint Antoine, Paris 75012, France
    Pharmacol Ther 131:80-90. 2011
    ....
  2. doi request reprint EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    Virginie Poindessous
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    Clin Cancer Res 17:6522-30. 2011
    ..We speculated that inhibition of surface receptors and ligands might only partly prevent oncogenic signaling whereas small-molecule tyrosine kinase inhibitors (TKI) would also influence intracellular signaling...
  3. doi request reprint Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Institut National de la Santé et de la Recherche Médicale U938, Paris, France
    Mol Cancer Ther 10:1481-9. 2011
    ..Taken together, our results provide a mechanistic basis to support clinical trials of PM01183 alone or in combination with cisplatin...
  4. doi request reprint The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
    ..The synthesis of these data allows us to conceive a future development focused on translational research...
  5. doi request reprint Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906
    Daniele G Soares
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem J 437:63-73. 2011
    ..These findings identify ATR as a central co-ordinator of the DNA-damage response to S23906, and provide a mechanistic rationale for combinations of S23906 and similar agents with checkpoint abrogators...
  6. doi request reprint From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
    ..Clarity regarding the clinical signal needed before launching a phase III study and optimized designs adapted to multiple agents are urgently needed for new trials...
  7. pmc Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
    ..The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer...
  8. doi request reprint The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators
    Céline J Rocca
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75571, France
    Biochem Pharmacol 80:335-43. 2010
    ..We further show that NER activity can be up-regulated without changes in ERCC1 expression...
  9. doi request reprint Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions
    Benoist Chibaudel
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 9:269-73. 2010
    ..A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials...
  10. ncbi request reprint Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models
    Amélie Petitprez
    Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris 75012, France
    Curr Pharm Des 19:958-64. 2013
    ..These results suggest that chemotherapy exposure may lead to creation of novel targets which could be exploited therapeutically...
  11. doi request reprint Stage II and stage III colon cancer: treatment advances and future directions
    Benoit Rousseau
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
    Cancer J 16:202-9. 2010
    ..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials...
  12. doi request reprint Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells
    Alexandre E Escargueil
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    J Cell Sci 121:1275-83. 2008
    ..Together, our findings provide novel insights into the subsequent fate of the stalled RNA polymerase II and demonstrate the essential role of the recycling process for transcriptional reinitiation and viability of mammalian cells...
  13. ncbi request reprint Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy
    Andrzej Skladanowski
    Group of Cancer Biology and Therapeutics, INSERM U673 and Université Pierre et Marie Curie, Hopital Saint Antoine, Paris, France
    Cell Cycle 6:2268-75. 2007
    ....